Sort   by:  
 Page size 
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Muscle Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000896 | MetabolomicsWorkbench
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Liver Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000894 | MetabolomicsWorkbench
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000893 | MetabolomicsWorkbench
TranscriptomicsmicroRNA profiling of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type
Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the chan...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-MTAB-3391 | biostudies-arrayexpress
TranscriptomicsGene expression analysis of H358 non-small cell lung cancer cells selected for resistance against erlotinib or wild-type
Erlotinib is a tyrosine kinase inhibitor (TKI) that is approved as a second-line monotherapy in patients with advanced non-small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest since overtime, many tumors develop resistance. To analyse the chan...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-MTAB-3387 | biostudies-arrayexpress
TranscriptomicsCharaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations
The non-small cell lung cancer (NSCLC) cell line HCC827 harbors an activating EGFR mutation (exon 19 deletion) that confers sensitivity to the FDA-approved EGFR inhibitor erlotinib. By applying the ClonTracer barcoding system, we were able to show the presence of pre-existing sub-populations in HCC8...
ORGANISM(S): Homo sapiens 
2014-10-07 | E-GEOD-62118 | biostudies-arrayexpress
TranscriptomicsExpression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib
Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant ...
ORGANISM(S): Homo sapiens 
2014-05-16 | E-GEOD-57156 | biostudies-arrayexpress
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Serum Metabolism In Vivo using Non-Targeted Metabolomics Analysis
Not available
ORGANISM(S): Mus musculus 
ST000895 | MetabolomicsWorkbench
TranscriptomicsGenome-wide analysis of EGFR inhibitor erlotinib treatment in Head and neck, squamous cell carcinoma's FADU, SQ20B and Cal 27
Chronic inflammation plays a significant role in tumor promotion, migration and invasion. Using microarray analysis, we observed a profound increase in genes involved in pro-inflammatory pathways in epidermal growth factor receptor inhibitor (EGFRI)-treated head and neck squamous cell carcinoma (HNS...
ORGANISM(S): Homo sapiens 
2014-04-08 | E-GEOD-45891 | biostudies-arrayexpress
GenomicsErlotinib-resistance selection
Selection of randomly mutated EGFR-libraries for erlotinib-resistance
PRJEB38789 | ENA
Sort   by:  
 Page size